167754-70-3

Upstream product

• 2043-61-0 cyclohexanecarbaldehyde 
• 167753-44-8 3-(1-benzylpiperidin-4-yl)-4-phenyl-3,4-dihydro-2(1H)-quinazolinone 
• 167754-42-9 N-[(2-aminophenyl)(phenyl)methyl]-1-benzylpiperidin-4-amine 

Downstream Products

• 265328-74-3 1-Butyl-3-[1-(Cyclohexylmethyl)piperidin-4-yl]-4-phenyl-3,4-dihydro-2(1H)-quinazolinone 

Relevant academic research and scientific papers

A novel class of sodium/calcium exchanger inhibitor: Design, synthesis, and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives

Design, synthesis, and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives as inhibitors of the sodium/calcium (Na+/Ca2+) exchanger are discussed. These studies, based on a lead compound 9a, which was identified in our library, involved systematic modification of three regions and revealed that (1) the 3,4-dihydro-2(1H)- quinazolinone having a tertiary amino alkyl side chain at the 3-position is essential for activity, (2) a nonsubstituted phenyl ring is most suitable for high activity, and (3) introduction of a 4-substituted piperidine moiety enhanced the activity, in particular 4-benzylpiperidin-1-yl showed strong inhibitory activity. Based on these SAR studies, a structurally novel and highly potent inhibitor against the Na+/Ca2+ exchanger, 12g (SM-15811), was discovered. In particular, SM-15811 directly inhibited the Na+-dependent Ca2+ influx via the Na+/Ca 2+ exchanger in cardiomyocytes with a high potency. The activity was almost two orders more potent than the lead compound 9a and SM-15811 exerted a protective effect against myocardial ischemic reperfusion injury. These Na +/Ca2+ inhibitors could have a therapeutic potential for the treatment of ischemic reperfusion injury.

Discovery of a novel potent Na+/Ca2+ exchanger inhibitor: Design, synthesis and structure-activity relationships of 3,4-dihydro-2(1H)-quinazolinone derivatives

Design, synthesis and structure-activity relationships for 3,4-dihydro-2(1H)-quinazolinone derivatives with the inhibitory activities of the Na+/Ca2+ exchanger are discussed. These studies based on lead compound 1a lead to the discovery of a structurally novel and highly potent inhibitor against the Na+/Ca2+ exchanger 4f (SM-15811), which directly inhibited the Na+-dependent Ca 2+ influx via the Na+/Ca2+ exchanger in cardiomyocytes with a high potency.

Quinazolinone derivatives possessing calcium uptake inhibiting activity

This invention is to provide quinazolinone derivatives, and their acid salts and quaternary ammonium salts, having an effect of preventing or treating diseases caused by calcium ion overload in cells, such as ischemic heart disease, ischemic cerebral disease and ischemic renal disease, and their usage. The quinazolinone derivatives are represented by the formula: STR1 typically, T represents an oxygen atom; Y represents a phenyl or cyclohexyl group; R1 represents a hydrogen or chlorine atom; R2 represents a hydrogen atom; ring W represents a benzene or pyridine ring; Z represents a group of the formula: STR2